Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3976879

CCn1cc(C(=O)O)c(=O)c2c(C)c(CCCN)ccc21.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.43
HSD17B10 Q99714 5/20 0.43
HPGD P15428 5/20 0.43
ALDH1A1 P00352 4/20 0.43
TSHR P16473 3/20 0.43
RAB9A P51151 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
APEX1 P27695 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 5/20 0.39
HTT P42858 3/20 0.39
FOXO1 Q12778 1/20 0.38
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
ABCC4 O15439 1/20 0.38
PKM P14618 1/20 0.38
PTGS1 P23219 1/20 0.38
DRD3 P35462 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3976883 0.86 LMNA (0.39) KDM4EHSD17B10HPGDALDH1A1TSHR
Trifluoroacetic Acid SCHEMBL3982421 0.78 KDM4E (0.55) KDM4EHSD17B10HPGDALDH1A1TSHR
SCHEMBL3983152 0.77 KDM4E (0.42) KDM4EHSD17B10HPGDALDH1A1TSHR
SCHEMBL8627262 0.72 ALDH1A1 (0.54) KDM4EHSD17B10HPGDALDH1A1TSHR
SCHEMBL5427785 0.72 DRD3 (0.56) KDM4EHSD17B10HPGDALDH1A1TSHR
SCHEMBL5427777 0.72 DRD3 (0.56) KDM4EHSD17B10HPGDALDH1A1TSHR
SCHEMBL5437272 0.71 KDM4E (0.60) KDM4EHSD17B10HPGDALDH1A1TSHR
SCHEMBL11548204 0.71 CHRM1 (0.44) KDM4EHSD17B10HPGDALDH1A1TSHR
SCHEMBL3976165 0.70 KDM4E (0.59) KDM4EHSD17B10HPGDALDH1A1TSHR
SCHEMBL3976181 0.70 KDM4E (0.59) KDM4EHSD17B10HPGDALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569550-B2 14 and 15 membered ring compounds GLAXO GROUP LIMITED (GB) 2009-08-04 US disclosed
US-20070185117-A1 Novel 14 and 15 membrered ring compounds GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
CN-1849328-A Novel 14 and 15 membered-ring compounds GLAXO GROUP LTD (GB) 2006-10-18 CN disclosed
EP-1628988-B1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LTD (GB) 2006-10-04 EP disclosed
EP-1628988-A1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-03-01 EP disclosed
WO-2004101586-A1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185117-A1 Novel 14 and 15 membrered ring compounds CYP51A1, LSS, IL17A KDM4E 3840/4885HSD17B10 668/4885HPGD 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.